19 81

Cited 35 times in

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

Authors
Wilson, MK; Pujade-Lauraine, E; Aoki, D; Mirza, MR; Lorusso, D; Oza, AM; du Bois, A; Vergote, I; Reuss, A; Bacon, M; Friedlander, M; Gallardo-Rincon, D; Joly, F; Chang, SJ; Ferrero, AM; Edmondson, RJ; Wimberger, P; Maenpaa, J; Gaffney, D; Zang, R; Okamoto, A; Stuart, G; Ochiai, K; Participants of the Fifth Ovarian Cancer Consensus Conference
Citation
Annals of oncology : official journal of the European Society for Medical Oncology, 28(4):727-732, 2017
Journal Title
Annals of oncology : official journal of the European Society for Medical Oncology
ISSN
0923-75341569-8041
Abstract
This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November 2015. Three important questions were identified: (i) What are the subgroups for clinical trials in ROC? The historical definition of using platinum-free interval (PFI) to categorise patients as having platinum-sensitive/resistant disease was replaced by therapy-free interval (TFI). TFI can be broken down into TFIp (PFI), TFInp (non-PFI) and TFIb (biological agent-free interval). Additional criteria to consider include histology, BRCA mutation status, number/type of previous therapies, outcome of prior surgery and patient reported symptoms. (ii) What are the control arms for clinical trials in ROC? When platinum is considered the best option, the control arm should be a platinum-based therapy with or without an anti-angiogenic agent or a poly (ADP-ribose) polymerase (PARP) inhibitor. If platinum is not considered the best option, the control arm could include a non-platinum drug, either as single agent or in combination. (iii) What are the endpoints for clinical trials in ROC? Overall survival (OS) is the preferred endpoint for patient cohorts with an expected median OS 12 months. However, PFS alone should not be the only endpoint and must be supported by additional endpoints including pre-defined patient reported outcomes (PROs), time to second subsequent therapy (TSST), or time until definitive deterioration of quality of life (TUDD).
MeSH terms
FemaleHumansNeoplasm Recurrence, Local/therapy*Ovarian Neoplasms/pathology*Ovarian Neoplasms/therapy*Research Design*
DOI
10.1093/annonc/mdw663
PMID
27993805
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
AJOU Authors
장, 석준
Files in This Item:
27993805.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse